

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8560889/publications.pdf>

Version: 2024-02-01

33
papers

2,638
citations

430874

18
h-index

414414

32
g-index

36
all docs

36
docs citations

36
times ranked

2991
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014, 46, 607-612.	21.4	560
2	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
3	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1713-1722.	3.6	195
4	Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. <i>European Journal of Endocrinology</i> , 2005, 153, 477-487.	3.7	158
5	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. <i>Nature Communications</i> , 2015, 6, 6044.	12.8	153
6	Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2015, 3, 45.	3.7	151
7	Transcriptome Analysis Reveals that p53 and β -Catenin Alterations Occur in a Group of Aggressive Adrenocortical Cancers. <i>Cancer Research</i> , 2010, 70, 8276-8281.	0.9	134
8	β -Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 328-336.	7.0	128
9	Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity. <i>Clinical Cancer Research</i> , 2007, 13, 844-850.	7.0	104
10	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	3.6	103
11	Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2010, 163, 129-138.	3.7	89
12	Mir-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer. <i>International Journal of Cancer</i> , 2018, 143, 944-957.	5.1	51
13	Adrenocortical Tumors. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1194-1201.	3.7	47
14	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3205.	3.6	44
15	Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. <i>European Journal of Endocrinology</i> , 2014, 170, 385-391.	3.7	37
16	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.	3.6	33
17	Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation. <i>Modern Pathology</i> , 2018, 31, 1708-1716.	5.5	29
18	KDM1A inactivation causes hereditary food-dependent Cushing syndrome. <i>Genetics in Medicine</i> , 2022, 24, 374-383.	2.4	27

#	ARTICLE	IF	CITATIONS
19	A Rare Cause of Hypertestosteronemia in a 68-Year-Old Patient: A Leydig Cell Tumor Due to a Somatic <i>GNAS</i> (<i>Guanine Nucleotide-Binding Protein, Alpha-Stimulating Activity Polypeptide</i>) Tj ETQq1 1 0.784204 rgBT f0verloc		
20	Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors. <i>Hormones and Cancer</i> , 2018, 9, 62-69.	4.9	18
21	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	3.7	16
22	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021, 11, 269.	2.5	14
23	Clinical and molecular prognostic factors in adrenocortical carcinoma. <i>Minerva Endocrinologica</i> , 2018, 44, 58-69.	1.8	12
24	A Feminizing Adrenocortical Carcinoma in the Context of a Late Onset 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1943-1944.	3.6	9
25	Adrenocortical Tumor with Two Distinct Elements Revealed by Combined 18F-Fluorodeoxyglucose Positron Emission Tomography and 131I Nor-Cholesterol Scintigraphy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3631-3632.	3.6	6
26	Rasch analysis for assessing unidimensionality and identifying measurement biases of malignancy scores in oncology. The example of the Weiss histopathological system for the diagnosis of adrenocortical cancer. <i>Cancer Epidemiology</i> , 2014, 38, 200-208.	1.9	4
27	18F-FDG PET reveals an adrenocortical carcinoma in a bilateral adrenal multinodular disease. <i>Endocrine</i> , 2019, 63, 188-189.	2.3	4
28	Preoperative Detection of Liver Involvement by Right-Sided Adrenocortical Carcinoma Using CT and MRI. <i>Cancers</i> , 2021, 13, 1603.	3.7	3
29	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2167-e2176.	3.6	3
30	Letter to the Editor from Berthon: "Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patient With Cortisol-Secreting Adrenocortical Adenoma". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4183-e4184.	3.6	1
31	An Ectopic Parathyroid Adenoma Mimicking a Carotid Body Paraganglioma. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa143.	0.2	1
32	A pheochromocytoma wrapped in an IgG4-related disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 929-930.	6.4	0
33	Recurrence of a Pheochromocytoma With TNEM127 Mutation Negative on 18F-FDOPA and 18F-FDG but Positive on 123I-MIBG and 68Ga-DOTATOC Imaging. <i>Clinical Nuclear Medicine</i> , 2022, 47, 251-252.	1.3	0